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The endogenous anti-tumor responses are limited in part by the absence of tumor-reactive
T cells, an inevitable consequence of thymic central tolerance mechanisms ensuring pre-
vention of autoimmunity. Here we show that tumor rejection induced by immune checkpoint
blockade is significantly enhanced in Aire-deficient mice, the epitome of central tolerance
breakdown. The observed synergy in tumor rejection extended to different tumor models,
was accompanied by increased numbers of activated T cells expressing high levels of Gzma,
Gzmb, Perforin, Cxcr3, and increased intratumoural levels of Cxcl9 and Cxcl10 compared to
wild-type mice. Consistent with Aire’s central role in T cell repertoire selection, single cell
TCR sequencing unveiled expansion of several clones with high tumor reactivity. The data
suggest that breakdown in central tolerance synergizes with immune checkpoint blockade in
enhancing anti-tumor immunity and may serve as a model to unmask novel anti-tumor
therapies including anti-tumor TCRs, normally purged during central tolerance.
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The immune system has evolved in response to the threat ofpathogenic microorganisms by carefully regulating theseresponses to clear the pathogen but also to prevent
immunity from damaging the host. The latter is primarily
achieved by establishing immune tolerance, a two-pronged
endeavor consisting of central and peripheral tolerance, ensur-
ing that “self-reactive” lymphocytes are either eliminated or
subjected to regulatory programs to limit any negative impact to
the host. Defects in the pathways involved in the establishment
and maintenance of tolerance give rise to autoimmunity, often
being associated with damage to specific tissues as a result of
infiltrating autoreactive lymphocytes.
In addition to protecting the body from pathogens, it is now
recognized that the immune system also plays a role in cancer
surveillance by removing cancerous, damaged, or stressed cells
that through modifications or mutations present molecules or
antigens that are deemed as nonself1. However, cancerous cells
often escape detection and clearance by the immune system
through mechanisms involving immune editing, enhanced reg-
ulatory T cell activity, and increased surface expression or
secretion of suppressive molecules2. Advances made over the last
two decades in the field of oncology have greatly enhanced the
survival rates of cancer patients. These advances include immu-
notherapies such as antibodies blocking the cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) and the programmed
cell death 1 (PD-1), and the development of chimeric antigen
receptor-modified T cells3,4. Despite these advances, cancer
remains the second leading cause of deaths in the United States
and therefore represents a tremendous burden on society5. The
high incidence of cancer and limited responses to current
therapies necessitates the development of new therapies to
improve patient survival.
Autoimmune regulator (Aire) plays a key role in establishing
central T cell tolerance thereby protecting against the develop-
ment of autoimmunity. Mutations in AIRE cause autoimmunity
against different organs in humans and mice6–8 accompanied by
a spectrum of manifestations, such as, autoimmune polyglandular
syndrome type-1 (APS-1), hypothyroidism, Addison’s disease,
and others9. Recently it was also shown that pneumonitis is
prevalent in patients with APS-1 characterized by high levels of
activated neutrophils and lymphocytes10. Aire is expressed in
medullary thymic epithelial cells (mTECs) where it functions as a
transcriptional regulator promoting the expression of tissue-
restricted self-antigens (TSAs). Self-reactive thymocytes that
recognize these TSAs with high affinity are eliminated through
apoptosis or differentiate into regulatory T cells (Tregs)11. Several
reports have also shown that both in mice and humans, Aire is
also expressed in secondary lymphoid organs by a specialized
population of cells, namely eTACs (extra-thymic Aire+ cells),
with a suggested role in regulating tolerance12–15, albeit this
contribution remains an open question.
Prior studies have indicated that deficiency in Aire promotes
the clearance of melanomas, due to the presence of self-reactive
T cells capable of recognizing self-antigens expressed on mela-
noma cells16–18. In addition, in vivo depletion of mTECs
expressing Aire using anti-RANKL antibodies resulted in
enhanced clearance of melanoma cells19. Furthermore, in
humans, single-nucleotide polymorphisms in AIRE have been
shown to be protective against melanoma20. Here we demonstrate
that breakdown in central tolerance in Aire-deficient mice, results
in enhanced rejection of multiple tumor types importantly in the
presence of different immune-checkpoint inhibitors. In an effort
to delineate the cellular and molecular mechanisms responsible
for this synergy we performed single-cell RNAseq and TCRseq.
We show that the antitumor response in Aire−/− mice is greatly
augmented, composed of multiple pro-inflammatory cell types
enlisting multiple pathways with the potential to serve as future
combination therapies.
Results
Aire deficiency results in potent antitumor rejection in com-
bination with PD-1 blockade. To evaluate whether defects in
central tolerance in combination with immune-checkpoint inhi-
bition affected tumor growth, Aire+/+ or Aire−/− mice were
implanted with the poorly immunogenic MC38 colon tumor
model21,22. PD-1 is a receptor expressed on T cells that is induced
upon activation resulting in decreased proliferation, cytotoxicity,
and cytokine production23. Mice were injected with anti-PD1 or
Isotype (Rat IgG2a) antibodies at the indicated time points and
tumor growth kinetics were monitored (Fig. 1a). Consistent with
prior reports24, we observed that PD1 blockade had a modest
reduction in tumor growth in Aire+/+ mice (Fig. 1b and Sup-
plementary Fig. 1a), whilst this difference was greatly augmented
in Aire−/− mice. Analysis of the tumor infiltrates revealed that
tumors from wild-type animals treated with anti-PD1 consisted
of significantly more infiltrating CD8+ T cells as previously
shown21 (Fig. 1c). However, Aire−/− mice treated with anti-PD1
had a significantly higher percentage of CD8+ T cells (15% vs.
10%), and an increase in the CD8/CD4 ratio and CD8/Treg ratio
compared with wild-type mice treated with anti-PD1 (Fig. 1c, e,
and Supplementary Fig. 1c). No major differences were observed
in the CD4+ TIL population (Fig. 1d). Importantly, the observed
increase was restricted to the tumors, as we did not observe any
marked differences in the levels of splenic CD8+ or CD4+ T cells
suggesting the response is driven by specific tumor antigens in the
tumors from Aire−/− (Supplementary Fig. 1d–f).
To further profile the observed antitumor response, we
performed RNAseq in tumors from Aire+/+ and Aire−/− mice
treated with anti-PD1. This showed that tumors from Aire-
deficient mice had a larger number of upregulated genes
compared with the wild-type mice (Supplementary Fig. 2a, b).
There was an enrichment of genes involved in T cell activity
(Fig. 2a) as well as chemokines and chemokine receptors (Fig. 2b).
There was a significant increase in the number of genes associated
with antitumor immune responses such as Cd3e, Cd8α, Ifnγ,
Tnfα, and FasL (Fig. 2c). Furthermore, there was an increase in
the expression of chemokines such as Xcl1, Cxcl9, Cxcl10, and
chemokine receptor Cxcr3 in the tumors from Aire−/−
(Supplementary Fig. 2c). High levels of Cxcl9 and Cxcl10 in
tumors correlate with increased recruitment of CD8+ T cells
expressing Cxcr325,26. Interestingly, chemokine profiling revealed
higher levels of CXCL10 in the serum from Aire-/- mice
(Supplementary Fig. 2d) in agreement with previous reports
showing high levels of CXCL10 in APS-1 patients27, suggesting a
potential mechanisms for the enhanced antitumor response. In
addition, tumors from Aire−/− mice had lower levels of
expression of Ptp4a1 and Meis2 which have been shown to
promote tumor progression and are associated with poor
survival28,29 (Supplementary Fig. 2e).
Aire deficiency results in potent melanoma rejection in com-
bination with immune-checkpoint blockade. We next wanted to
test whether Aire−/− mice also displayed increased antitumor
activity against B16F10 melanoma. To this end, we implanted
mice with B16.F10 cells and treated mice with anti-CTLA4 or
isotype antibodies on days 3, 7, 10, and 14 and tumor growth
kinetics were monitored. Consistent with published results16,
anti-CTLA4 treatment had a profound effect on tumor growth in
the Aire−/− mice compared with wild type (Fig. 3a). Interestingly,
Aire−/− mice treated with isotype displayed increased antitumor
activity over the wild type also treated with isotype control
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antibody. Profiling of tumor infiltrates revealed that anti-CTLA4
blockade increased the percentage of both CD4+ and CD8+
T cells in wild-type mice over isotype (Supplementary Fig. 3a, b).
However, Aire−/− mice treated with anti-CTLA4 had a sig-
nificantly higher percentage of CD4+ and CD8+ T cells and an
increase in the CD8/CD4 ratio and CD8/Treg ratio over the wild
type also treated with anti-CTLA4 (Supplementary Fig. 3c, d). We
observed similar results using the MC38 tumor model in Aire+/+
and Aire−/− mice treated with anti-CTLA4 or isotype antibodies
(Supplementary Fig. 3e). We next wanted to determine if the
enhanced antitumor activity of Aire−/− mice could be unmasked
with another immune-checkpoint inhibitor. To this end, we
implanted mice with B16F10 melanoma tumors treated with anti-
PD1 or isotype antibodies on days 3, 7, 10, and 14 and tumor
growth kinetics were monitored. This line of experimentation
showed that Aire−/− mice displayed reduced tumor growth in the
presence of anti-PD1 antibody over the wild type (Fig. 3b). We
next wanted to determine if there were differences in the levels of
cytotoxicity of CD8+ TILs from Aire+/+ and Aire−/− mice. To
this end, we isolated CD8+ TILs from Aire+/+ and Aire−/− mice
treated with anti-PD1 or isotype antibodies, mixed with tumor
cells and measured the activity of lactate dehydrogenase (LDH),
which is released from the cytosol of damaged cells into the
supernatant30. This line of experimentation showed that direct
cytotoxicity testing against B16F10 target cells resulted in
enhanced activity for CD8+ TILs from Aire−/− mice treated with
anti-PD1 as compared with wild type when effector-to-target
ratios were at least 7.5:1 (Fig. 3c). In addition, there was an
increase in the levels of IFNγ and TNFα released by the CD8+
TILs from Aire−/− mice treated with anti-PD1 compared with
wild type (Supplementary Fig. 3f, g). Interestingly, the levels of
the two cytokines analyzed were similar between CD8+ TILs
from Aire−/− mice treated with anti-PD1 or isotype suggesting
that the cytolytic activity of CD8+ TILs Aire−/− mice is greatly
enhanced by antagonizing the PD1 pathway.
To further elucidate the magnitude of the anti-melanoma
response observed in Aire−/− mice, we performed RNAseq in
tumors from Aire+/+ and Aire−/− mice treated with anti-CTLA4.
These results revealed that tumors from Aire-deficient mice had a
larger number of upregulated genes compared with the wild-type
mice (Fig. 4a and Supplementary Fig. 4a). Similar to our prior
observations with the MC38 model, there was a significant
increase in the number of genes associated with antitumor
immune responses such as Ifnγ, Gzmb, Perforin, Cxcl9, Cxcl10,
and levels of Cxcr3 trended higher in Aire−/− mice (Fig. 4b),
supporting the hypothesis that defects in central tolerance
provide a conducive immunological milieu that synergizes with
various immune-checkpoint therapies across different tumor
types.
Single-cell analysis reveals drastic changes in tumor infiltrates
from Aire−/− mice. To further elucidate the cellular and mole-
cular changes that may account for the enhanced antitumor
activity observed in Aire−/− mice, we performed single-cell
















































































































































Fig. 1 Aire−/− mice displayed increased tumor killing in combination with PD-1 blockade. a Schematic depicting antibody treatment regimen in Aire+/+
and Aire−/− implanted with MC38. Mice were injected with Isotype or anti-PD1 antibodies at 5 mg/kg on days 0, 3, 7, 10, and 14. b Growth kinetics of
MC38 tumors in Aire+/+ and Aire−/− treated with Isotype or anti-PD1 (n= 8 per group). c, d Percentage of intra-tumoral CD8+ or CD4+ T cells from
Aire+/+ and Aire−/− treated with isotype or anti-PD1 (n= 5 per group) at day 23. Cells were gated on live cells and percentages were determined out of
total CD45+ cells. e Ratio of CD8+ to CD4+ T cells. Data are represented as mean ± SEM, (*P < 0.05; **P < 0.01; ***P < 0.001), one-way ANOVA with
Tukey’s test.
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mice were implanted with tumors and anti-PD1 or isotype
antibodies administered on days 0, 3, 7, 10, and 14 and tumor
infiltrates were analyzed on day 19. We sorted the intra-tumoral
and splenic CD45+ populations (Supplementary Fig. 5a) and
individually sequenced cells from each tissue (Supplementary
Table 1). Unbiased clustering was performed using the Seurat
package with cell populations visualized in UMAP dimensionality
reduction plots. The analysis revealed ten distinct clusters in the
combined intra-tumoral and splenic CD45+ populations, each
with a unique gene expression profile (Fig. 5a). The clustering of
spleens and tumors separately revealed the source of the clusters
identified (Supplementary Fig. 5b). Major cell types comprised
T cells (CD3e+), B cells (CD79a+), macrophage/myeloid (Msr1+
C1qb+), dendritic cells (Clec9a+), pDCs (Siglech+), NK cells
(Ncr1+), and neutrophils (S100a8+) (Fig. 5b). Based on specific
cell markers, T cells were furthered clustered into activated CD8+
(Clusters 0 and 2), CD8+ naïve (Cluster 6), CD4+ T cells (Cluster
10), and regulatory T cells. The clusters identified expressed
markers associated with each specific cell type such as Cd4, Cd8α,
and Foxp3.
Clustering of each individual condition tested revealed drastic
changes in percentages of several populations in Aire−/− mice
(Fig. 5c). We observed that anti-PD1 treatment resulted in
increased levels of activated CD8+ T cells in both Aire+/+ and
Aire−/− compared with the isotype treated animals (Clusters 0
and 2). However, there was a ~3 and ~3.6-fold increase in the
percentage of activated CD8+ T cells in tumors from Aire−/−
mice treated with anti-PD1 over wild type (Fig. 5d). Congruent
with the initial observations made in Fig. 1, we did not observe
any changes in the populations identified in the spleen suggesting
the response is tumor specific (Supplementary Fig. 5c).
The activated CD8+ T cells (Cluster 0) in tumors from Aire−/−
mice treated with anti-PD1 had higher levels of the antitumor
genes Gzmb, and Perforin compared to wild type (Supplementary
Table 2). In addition, the activated CD8+ T cells from Cluster 2
had increased levels of Gzma as well as Stat1 (Supplementary
Table 3), the latter which has been shown to be necessary for the
development of antitumor cytolytic activity31. Furthermore, these
activated CD8+ T cells expressed high levels of the integrin
Cd103, the transcription factor Egr1, and reduced levels of Klf2
which have been associated with the formation of tumor-resident
memory cells (TRM)32. TRM cells have recently been shown to be
retained within the tumor microenvironment and their presence
is associated with better survival32,33.
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Fig. 2 Tumors from Aire−/− mice have increased levels of cytotoxic genes. a, b Heatmaps depicting differentially regulated genes associated with T cell
receptor signaling or chemokine signaling in tumors from Aire+/+ (n= 4) and Aire−/− (n= 3) mice treated with anti-PD1. Differentially regulated genes were
defined with log2 fold changes of 1.5 in either up or down direction and with p values <0.01; TPM transcripts per million. The expression value of each gene
was divided by the median expression of the same gene across all samples. c Transcript levels of Cd3e, Cd8α, Ifnγ, Tnfα, and FasL in tumors from Aire+/+ and
Aire−/− mice. TPM transcripts per million. Data are represented as mean ± SEM, (*P < 0.05; **P < 0.01; ***P < 0.001), by Student’s t test. TPM values are
provided in Supplementary Data 1.
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There were also changes in the levels of NK cells, with the
Aire−/− mice treated with anti-PD1 having more than the wild
type (Fig. 5c, d). These NK cells express high levels of the cell-
cycle regulator Pim-1 (Supplementary Table 4), and its over-
expression has been suggested to protect NK cells from
apoptosis34,35. Intra-tumoral macrophages have been shown to
constitute the largest population and undergo drastic changes
following immune-checkpoint therapy36. Our results showed that
anti-PD1 treatment reduced the number of macrophages in
tumors from both Aire+/+ and Aire−/− compared with the
isotype treated groups. However, the number of macrophages was
strikingly lower with ~3.8-fold less in the tumors from Aire−/−
mice treated with anti-PD1 over the wild type (Fig. 5d). This
decrease was also confirmed by determining the percentage of
tumor infiltrating macrophages (Supplementary Fig. 5d). Despite
the lower numbers, the macrophages present had increased levels
of interferon stimulated genes such as Ifitm1, Gpb2, Gbp4, and
Ifi47 (Supplementary Data 3). In addition, there were increased
levels of the M1 macrophage marker Nos2 and high expression of
the T cell chemoattractant Cxcl9. M1 macrophages produce high
amounts of ROS and nitrogen radicals which have strong
tumoricidal activity, and the secretion of Cxcl9 recruits
Th1 cells to the tumor37,38. Altogether, these data suggest that
the combination of immune-checkpoint blockade and breakdown
in central tolerance orchestrates a multicellular recruitment of
different immune cell types with pro-inflammatory characteristics
at the tumor site and allows for unmasking of potential novel
approaches for combination therapies, beyond T cells.
Expansion of unique CD8+ TILs in Aire−/− mice. Given the
remarkable changes in the levels of CD8+ T cells in the tumors
from Aire−/− treated with anti-PD1 compared with wild type, we
wanted to determine if there were qualitative changes in sub-
populations that may account for the results seen. To this end, we
sorted, captured, and sequenced intra-tumoral or splenic CD8+
T cells from Aire+/+ and Aire−/− treated with anti-PD1 or iso-
type resulting in individually sequenced cells from each tissue
respectively (Supplementary Table 5). We performed clustering of
the intra-tumoral and splenic CD8+ T cells using the Seurat
package which identified 14 unique cell clusters (Fig. 6a). The
major separation of clusters was primarily driven by the tissue
source of the CD8+ T cells, and all conditions tested were well
represented in both tissues (Supplementary Fig. 6a, b). The intra-
tumoral CD8+ T cells expressed very low levels of the naïve T cell
marker L-selectin (CD62L) and high levels of the activation
marker Cd69 (Fig. 6b). In addition, CD8+ TILs were character-
ized as having a distinctly pro-inflammatory signature with high
levels of 4-1BB, Lag3, Gzma, Gzmb, Gzmk, and Gzmc (Fig. 6b).
We next determined the composition of each condition per
cluster to identify any changes. We found that more than 50% of
cluster 6 was composed of CD8+ TILs from Aire−/− treated with
anti-PD1 (Fig. 6c and Supplementary Fig. 6c). These cells were
characterized as expressing high levels of genes associated with
T cell activation such as Lmna, Gzma, Nr4a1, Cd69, Pdcd1, Tnf,
and FasL (Supplementary Data 4). Furthermore, these cells had
increased levels of the chemokine receptors Cxcr3 and Cxcr6.
Although not as striking as cluster 6, we also observed CD8+ TILs
from Aire−/− mice treated with anti-PD1 were overrepresented in
cluster 9. Interestingly, these cells expressed high levels of inter-
feron stimulated genes such as Cxcl10, Isg15, Ifit3, Ifit1, Rsad2,
and Mx1 (Supplementary Data 5). Type-I interferons have been
shown to act directly on CD8+ T cells where they promote
activation and differentiation39.
Given the central role of Aire in shaping the TCR repertoire to
remove autoreactive T cells, we calculated the TCR alpha and beta
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Fig. 3 Aire−/− mice displayed increased melanoma killing in combination with PD-1 or CTLA4 blockade. a Growth kinetics of B16.F10 tumors in Aire+/+
and Aire−/− treated with Isotype or anti-CTLA4 (n= 9 per group). b Growth kinetics of B16.F10 tumors in Aire+/+ and Aire−/− treated with Isotype or anti-
PD1 (n= 10 per group). c Increased cytotoxicity of CD8+ TILs from Aire−/− mice treated with anti-PD1 (n= 3 per group). Data are represented as mean ±
SEM, (*P < 0.05; **P < 0.01; ***P < 0.001), by one-way ANOVA with Tukey’s test.
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chains CDR3 repertoire diversity of the CD8+ TILs and splenic
CD8+ T cells in knockout and wild-type mice using Shannon’s
diversity index. These results showed that CD8+ TILs from Aire−/−
mice treated with anti-PD1 or isotype have increased clonal
diversity than the wild type (Fig. 7a). The diversity of the TCR
repertoire of CD8+ T cells in the tumor was significantly less than
in the spleen (Supplementary Fig. 7a), probably as a result of T cell
clones that were selectively expanded in the tumor. Interestingly,
PD1 antagonism reduced the clonal diversity of CD8+ TILs from
Aire+/+ and Aire−/− mice suggesting that selective clones are
recruited to the tumor microenvironment to control tumor growth.
Such decrease in clonal diversity has previously been observed in
patients suffering from glioblastoma treated with anti-PD1 antibody
and correlates with improved survival40.
Given the increased CD8+TIL diversity observed in Aire−/−
mice treated with anti-PD1, we next wanted to determine if the
most expanded T cell clones were tumor reactive. To this end, we
used a JRT3 cell line, which normally does not express surface
CD3 or the TCR α/β heterodimer, and introduced mCD28,
mCD8α, and mCD8β. The cells were also engineered to express
luciferase under an AP-1 promoter. To confirm that the cells
would express luciferase upon activation, we treated the cells with
PMA/Ionomycin and observed robust luciferase activity after 2
and 6 h (Supplementary Fig. 7b). To ensure that expression of a
TCR α/β heterodimer would lead to activation of the AP-1
reporter, we engineered cells with a TCR that binds a known
epitope on MC38 cells 41. To this end, we incubated the
engineered cells with tumor cells which resulted in robust
activation of the AP-1 promoter (~16 fold higher than a control
TCR) as measured by luciferase activity (Supplementary Fig. 7c).
We next introduced the TCR sequences of clones whose
combined frequency accounted for more than 20% of the
sequences analyzed (Supplementary Table 6) into a lentiviral








































































Fig. 4 Tumors from Aire−/− mice treated with anti-CTLA4 have increased levels of cytotoxic genes. a Heatmap depicting the differentially regulated
genes in tumors from Aire+/+ (n= 6) and Aire−/− (n= 6) mice treated with anti-CTLA4. Differentially regulated genes were defined with log2 fold
changes of 1.5 in either up or down direction and with p values < 0.01; TPM transcripts per million. The expression value of each gene was divided by the
median expression of the same gene across all samples. The genes found to be differentially regulated were grouped according to different biological
pathways (columns on left shaded in red). b Levels of Ifnγ, Gzmb, Prf1, Cxcl9, Cxcl10, and Cxcr3 in tumors from Aire+/+ and Aire−/− mice. TPM,
transcripts per million. Data are represented as mean ± SEM, (*P < 0.05; **P < 0.01; ***P < 0.001), by Student’s t test. TPM values are provided in
Supplementary Data 2.
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to recognize tumors and engage downstream signaling pathways
leading to induction of AP-1 luciferase activity. The most
frequent clone, representing ~10% of the sequences analyzed,
contained two TCR α sequences and a shared β sequence, and
thus two independent cell lines, named TCR 1.1 and TCR 1.2
were generated to determine their tumor reactivity (Supplemen-
tary Table 6). We utilized two cell lines as negative controls, TCR
Control 1 and 2, expressing TCRs which were previously
identified as non-tumor reactive. We observed surface expression
of TCR α/β and CD3 in the cells transduced with the TCR-
expressing vector, while the cells transduced with empty vector
did not show any expression (Supplementary Fig. 7d). To test
whether the engineered cells expressing the identified TCRs were
indeed tumor reactive, we mixed them with tumor cells and
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Fig. 5 Single-cell analysis reveals changes in intra-tumoral cell populations in tumors from Aire+/+ and Aire−/− mice. a UMAP plot depicting the
clusters from splenic and tumor CD45+ cells. The cluster numbers correspond to individual cell populations described below the UMAP plot. b Individual
UMAP plots from splenic and tumor CD45+ cells depicting the expression of cell markers associated with cell clusters identified in Fig. 5a. T cells (CD3e+),
B cells (CD79a+), macrophage/myeloid (Msr1+ C1qb+), dendritic cells (Clec9a+), pDCs (Siglech+), NK cells (Ncr1+), and neutrophils (S100a8+).
c UMAP plots depicting the unsupervised clustering of tumor CD45+ cells in Aire+/+ and Aire−/− treated with Isotype or anti-PD1. d Bar graph depicting
the composition of each cluster identified in tumor CD45+ cells from Aire+/+ and Aire−/− mice treated with Isotype or anti-PD1. Transcriptional changes in
all cell types identified across all conditions are included in Supplementary Data 6.
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assessed luciferase activity 6 h later. This line of experimentation
showed that the engineered cell lines had significantly more
luciferase activity in the presence of tumor cells compared with
the negative controls (Fig. 7b). In addition, the fold changes in
luciferase activity for the engineered cells over the non-tumor
reactive TCR Control 1 cells ranged between ~12 and ~90.3-fold
(Fig. 7b), comparable or higher to the previously identified TCR41
(Supplementary Fig. 7c) highlighting the potency of the TCRs
from the expanded clones in the tumors from Aire−/− mice.
Interestingly, there was variation in the reactivity between the
engineered cells expressing the identified TCRs. The cells
expressing TCR 4 had the highest levels of reactivity compared
with the cells expressing TCR 2 perhaps due to differences in the
levels of antigen on the tumor cells. Altogether, these results
suggest that PD1 blockade in Aire−/− results in the expansion of
intra-tumoral CD8+ T cells capable of recognizing tumor cells,
potentially harboring unique tumor TCRs.
Discussion
We report that deficiency in central tolerance in combination
with immune-checkpoint blockade results in an enhanced
immune response leading to significantly reduced tumor growth
for both melanoma and colorectal cancers. Using the colorectal
tumor model MC38 and melanoma B16.F10, we showed that
Aire−/− mice treated with anti-PD1 or anti-CTLA4 controlled
tumor growth significantly better than the wild-type mice
(Figs. 1b, 3a, b) and was accompanied by an increased infiltration
of activated CD8+ T cells into the tumors. Transcriptional pro-
filing showed that tumors from Aire−/− had significantly more
upregulated genes associated with antitumor activity such as Tnf,
FasL, Xcl1, Cxcl9, Cxcl10, and Cxcr3 compared to wild-type mice
(Fig. 2a–c and Supplementary Fig. 2a). In addition, anti-PD1
treatment resulted in the downregulation of many genes such as
Ptp4a1 and Meis2 (Supplementary Fig. 2e) which have been
implicated in the development and progression of cancer28,29.
High dimensional analysis of tumor infiltrates from Aire−/−
and Aire+/+ mice treated with anti-PD1 showed dramatic
changes in several key immune populations in addition to CD8+
T cells, such as NK cells, and macrophages (Fig. 5c, d). The CD8+
TILs from Aire−/− mice expressed high levels of the cytolytic
molecules Gzma, Gzmb, and Perforin. Interestingly, we also
observed higher levels of CD8+ T cells expressing markers
associated with tumor-resident memory cells such as Cd103 and
Egr1. Although to date no reports have linked the generation of
TRMs to Aire deficiency, the presence of these cells has been
shown to correlate with improved patient survival and several





















































Fig. 6 Sub-clustering of CD8+ TILs show enrichment of highly cytotoxic cells in Aire−/− mice. a UMAP plot of splenic and tumor CD8+ T cells from
Aire+/+ and Aire−/− mice treated with Isotype or anti-PD1. Cluster numbers correspond to individual cell subpopulations. b Individual UMAP plots from
splenic and tumor CD8+ T cells depicting the expression of cell markers associated with cell clusters identified in Fig. 6a. c Heatmap depicting the composition
of each cluster identified in the UMAP lot shown in Fig. 6a. Transcriptional changes for all clusters can be found in Supplementary Data 7.
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population32,33,42. In addition, we identified a population of
CD8+ T cells that expressed high levels of type-I interferon sti-
mulated genes (Fig. 6c and Supplementary Data 7). Several stu-
dies have shown that type-I IFNs act directly on CD8+ T cells to
increase production of Ifnγ and promote their survival39,43,44.
Given that the main role of AIRE in establishing central tol-
erance is to remove autoreactive CD4+ and CD8+ T cells, it was
unexpected to find differences in the macrophage population of
the tumors profiled. Tissue-associated macrophages represent a
significant portion of the infiltrating leukocytes in the tumor
microenvironment where they have been shown to play key
roles45. We observed that while tumors from Aire−/− mice
treated with anti-PD1 had significantly less macrophages they
expressed high levels of the M1-marker Nos2. Furthermore, these
macrophages expressed higher levels of several type-I interferon
stimulated genes which are characteristic of the M1 phenotype46.
PD-1 blockade has recently been shown to promote the differ-
entiation from M2 macrophages to M1 resulting in regression of
lung metastases of osteosarcoma47. Furthermore, treatment with
anti-PDL1 antibody resulted in the polarization of macrophages
towards the pro-inflammatory phenotype48. Interestingly, auto-
reactive T cells promoted ocular infiltration of macrophages in a












































































Fig. 7 Increased expansion and clonal diversity of CD8+ TILs in Aire−/− mice. a Shannon diversity was calculated for clones defined by the
CDR3 sequences of TCR alpha and beta chains from Aire+/+ and Aire−/− MC38 tumor bearing mice treated with isotype or anti-PD1 antibodies. Tumors
were harvested on Day 19. Data were bootstrapped 50 times at the indicated sample sizes along the x axis. Interpolated lines (solid) were determined
based on sample sizes smaller than the actual sample size. Extrapolated lines (dashed) were determined with sample sizes larger than the actual sample
size. Extrapolated lines (dashed) were determined with sample sizes larger than the actual sample size. b Activation of the engineered T cells expressing
the identified TCRs (Supplementary Table 6). T cells were mixed with increasing concentrations of tumor cells and luciferase activity was assessed 6 h
later (n= 3 per group). Fold-change, indicated with × was determined by dividing the RLU values of each TCR by the values of TCR Control 1. Data are
represented as mean ± SEM, (*P < 0.05; **P < 0.01; ***P < 0.001), by one-way ANOVA with Tukey’s test. Full list of CDR3 sequences for all clones is
included in Supplementary Data 8.
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Sjogren’s syndrome model using Aire−/− mice49. It is con-
ceivable, therefore, that macrophages in Aire−/− mice contain
transcriptional programs which in combination with PD-1
blockade directs them toward the more tumoricidal M1
phenotype.
The transcriptional profiling of the tumor models used in this
study revealed increased levels of the chemokines Cxcl9 and
Cxcl10 in tumors from Aire−/− mice (Figs. 2b, 4b). Interestingly,
we also observed increased levels of Cxcl10 in serum consistent
with a previous study in humans suffering from APECED27.
Cxcl9 and Cxcl10 have been shown to play significant roles in
recruiting Cxcr3+ T cells into the tumor and high levels correlate
with improved patient survival50. A recent study showed that
Cxcr3+ CD8+ T cells underwent rapid proliferation and were
more activated in the presence of anti-PD126. It is possible that
the autoimmunity observed in Aire−/− mice and humans with
APECED results in higher levels of circulating chemokines such
as Cxcl9 and Cxcl10 produced by macrophages or dendritic cells
which when present in tumors leads to enhanced recruitment of
T cells, supporting an intricate feedback loop between innate and
adaptive immune cells in orchestrating an enhanced antitumor
response in Aire−/− mice.
In addition we showed that Aire−/− mice treated with anti-
CTLA4 controlled melanoma growth better than wild type
(Fig. 3a) as previously reported16. However, we observed
increases in the percentages of both CD4+ and CD8+ T cells in
Aire−/− treated with anti-CTLA4 over the wild type in contrast to
what was previously observed. In depth transcriptional profiling
of these tumors showed a higher number of upregulated anti-
tumor genes in Aire−/− treated with anti-CTLA4 such as Ifng,
Gzmb, and Perforin (Fig. 4a, b). Importantly, the observed
synergy in tumor rejection extended to PD1 immunotherapy also,
as evidenced by the enhanced tumor rejection in Aire−/− mice
treated with anti-PD1 and increased cytolytic activity of CD8+
TILs (Fig. 3b, c). The anti-melanoma response observed in
Aire−/− mice has been attributed to the presence of autoreactive
T cells, which would normally be eliminated by Aire-regulated
central tolerance mechanisms. Aire regulates the expression of
several self-antigens in mTECs expressed by melanoma cells such
as gp100, TRP-1, and tyrosinase17,18. In addition, mTECs have
been shown to express other tumor-associated antigens such as
MUC1 and CEA51. It would be interesting to profile melanoma
TILs in Aire-deficient mice to identify specific TCRs with
enhanced antitumor activity. Our results showed a greater clonal
diversity of CD8+ TILs from Aire−/− mice (Fig. 7a) and more
importantly the most highly expanded TILs were capable of
recognizing tumor cells (Fig. 7b).
Taken together, the combination of immune-checkpoint
blockade and breakdown in central tolerance orchestrate a
sculpting of the tumor landscape that enhances tumor rejection
and importantly provides an experimental platform for
unmasking of potential novel cellular and molecular approaches.
Although current inhibitors have greatly improved survival, their
efficacy is limited to a minority of patients52 and efforts to
identify combination agents remains high. It was shown that
depletion of mTECs using anti-RANKL resulted in enhanced
killing of melanoma tumors and this has been proposed as a novel
therapy19,53. Pursuing strategies that increase the number of
antitumor T cells and modulate other cell types involved in tumor
clearance will be of direct clinical relevance.
Methods
Mice. 8-week-old Aire+/+ and Aire−/− littermates (JAX, stock no. 004743) were
purchased from Jackson Laboratories. All mice were used in accordance with
guidelines from the Regeneron Pharmaceuticals Animal Care and Use Committee.
All experiments involving mice were performed with the approval of the Regen-
eron Pharmaceuticals Animal Care and Use Committee.
Tumor models. MC38 is a C57BL/6-derived colon tumor, and B16-10 is C57BL/6-
derived melanoma tumor. The cells were maintained in complete DMEM com-
posed of 10% FBS (Gibco, stock no. 26170043), and 1 mM penicillin/streptomycin
(Gibco, Stock no. 15140148). Tumor cells were incubated as a monolayer in a
humidified CO2 incubator at 37 °C. Cells were maintained at ~70% confluency, and
harvested with 0.05% trypsin (Gibco, Stock no. 15400054), washed and suspended
in PBS before injection in mice. All cells lines used were mycoplasma free, and were
authenticated using CellCheck (Short Tandem Repeat (STR) Profiling) by Idexx
BioAnalytics.
Tumor implantation, antibody treatment, and measurement. Mice were injec-
ted with 4 × 105 MC38 cells, or 2 × 105 B16-F10 cells subcutaneous (s.c). into the
right flank. anti-PD1 blocking antibody (BioXcell, Clone RMP1-14, Stock no.
BE0146) and isotype (BioXcell, Clone 2A3, Stock no. BE0089) were injected i.p. in
100 μL of PBS at a concentration of 5 mg/kg on days 0, 3, 7, 10, and 14. anti-
CTLA4 blocking antibody (BioXcell, Clone 9D9, Stock no. BE0164) and isotype
(BioXcell, Clone MPC-11, Stock no. BE0086) were injected i.p. in 100 μL of PBS at
a concentration of 5 mg/kg on days 0, 3, 7, 10, and 14. Tumor volumes were
measured blindly using a digital calipers and calculated using the formula L ×W ×
W × 0.5 where L is the longest dimension and W is the perpendicular dimension54.
Flow cytometry. Tumors were enzymatically dissociated into single cells suspen-
sions using Miltenyi Biotec’s Mouse Tumor Dissociation Kit (Miltenyi, stock no.
130-096-730) and following manufacturer’s instructions. Single-cell suspensions of
spleen and lymph nodes were prepared by mechanical dispersion. Cell suspensions
were incubated with LIVE/DEAD fixable blue dead cell stain (Invitrogen, Stock no.
L23105) for 10 min at room temperature, washed twice with Cell Staining Buffer
(Biolegend) and incubated with anti-CD16/CD32 blocking antibody (Biolegend,
Stock no. 101302) for 10 min on ice. Cells were washed twice with Cell Staining
Buffer, resuspended in staining antibody cocktail, and incubated on ice in the dark
for 20 min. Cells were washed twice with Cell Staining Buffer and fixed overnight
with Fixation Buffer (eBioscience Stock no. 00-8222-49). FoxP3-e450 (Clone FJK-
16s, eBioscience, Cat. #48-5773-82), CD45-BV510 (Clone 30-F11, Biolegend, Cat.
#103138), PD1-BV605 (Clone JA3, BD Bioscience, Cat. #563059), NK1.1-BV650
(Clone PKI36, BD Bioscience, Cat. #564143), GITR-BV711 (Clone DTA-1, BD
Bioscience, Cat. #563390), CD4-BV786 (Clone RM4-5, BD Bioscience, Cat.
#563727), CD11B-BUV395 (Clone M1/70, BD Bioscience, Cat. #563553), CD44-
BUV737 (Clone IM7, BD Bioscience, Cat. #564392), CD8-BUV805 (Clone 53-6.7,
BD Bioscience, Cat. #564920), CD3-Alexa 700 (Clone 17A2, eBioscience, Cat. #56-
0032-82), Lag3-APC-Cy7 (Clone eBioC9B7W, eBioscience, Cat. #47-2231-82),
Tim3-PE (Clone RMT3-23, eBioscience, Cat. #12-5870-82), CTLA4-PE-CF594
(Clone UC10-4F10-11, BD Bioscience, Cat. #564332), 2B4-PE-Cy7 (Clone m2B4
(B6)458.1, Biolegend, Cat. #133512), Live/Dead Blue-Fixable Blue Dye (Invivogen,
Cat. #L-23105), and KLRG1-FITC (Clone 2F1, eBioscience, Cat. #11-5893-82).
RNA preparation. Tissue samples (tumors, spleens, and lymph nodes) were col-
lected in RNAlater Stabilization Solution (ThermoFisher, Cat. #AM7020), and total
RNA was purified from all samples using MagMAX™-96 for Microarrays Total
RNA Isolation Kit (Ambion by Life Technologies) according to manufacturer’s
specifications. Genomic DNA was removed using MagMAX™Turbo™DNase Buffer
and TURBO DNase from the MagMAX kit listed above (Ambion by Life Tech-
nologies). Strand-specific mRNAseq libraries were prepared from total RNA using
the KAPA Stranded mRNA-Seq Kits (Kapa Biosystems). Twelve-cycle PCR was
performed to amplify libraries, and sequencing was performed on Illumina
HiSeq®2500 (Illumina) by multiplexed single-read run with 80 cycles.
RNAseq read mapping and statistical analysis of differentially expressed
RNA. Raw sequence data (BCL files) were converted to FASTQ format via Illumina
bcl2fastq v2.17, and reads were decoded based on their barcodes and read quality
was evaluated with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Reads were mapped to the mouse genome (mm10) using ArrayStudio
software (OmicSoft, Cary, NC) allowing for two mismatches. Reads mapped to the
exons of a gene were summed at the gene level. Differential expressed genes were
identified by the DESeq2 R package55 and significantly perturbed genes were
defined with fold changes of at least 1.5 in either up or down direction and with
p values < 0.01.
Single-cell RNA sequencing and read mapping. Aire+/+ and Aire−/− mice were
implanted with 4 × 105 MC38 cells and treated with anti-PD1 blocking antibody
and isotype at 5 mg/kg on days 0, 3, 7, 10, and 14. Tumors from 4 to 6 mice for
each condition were collected on Day 19 post implant, processed into single-cell
suspensions and pooled to obtain enough cells for single-cell RNA sequencing.
Spleens were also collected from each condition, processed, and pooled. Single-cell
suspensions of MC38 tumors or spleens were sorted for CD45+ or CD8+ and
collected into tubes containing PBS with 0.04% BSA. The cell suspensions were
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loaded on a Chromium Single Cell Instrument (10X Genomics) and RNA libraries
were prepared using Chromium Single Cell 3′ Library, Gel Beads and Multiplex Kit
(10X Genomics). Paired-end sequencing was performed on Illumina NextSeq500
where Read 1 was used for unique molecular identifier (UMI) and cell barcode
while Read 2 was used for 55-bp transcript read. Sample demultiplexing, alignment,
filtering, and UMI counting were performed on Cell Ranger Single-Cell Software
Suite (10X Genomics).
Single-cell data analysis. Single-cell analysis was carried out using version 2 of
the Seurat R package56,57. Cells with fewer than 200 genes detected or >20% of
reads mapping to mitochondrial genes were discarded from analysis. Gene
expression values for each cell were normalized and scaled due to variation in cell-
cycle stage and mitochondrial rate, and were regressed out as described pre-
viously56. The number of UMI was also regressed out to correct for variation in
sampling depth of these cells. The genes used for principal component analysis
were the 1000 genes with the highest dispersion (variance to mean ratio) for genes
with mean UMI between 0.0125 and 8 and variance above 0.5. Genes were divided
into 20 bins of equal width based on their average expression and dispersion z
scores were calculated within these bins. Cells were then partitioned into clusters
(Seurat FindClusters function) and visualized using the t-distributed stochastic
neighbor embedding (t-SNE) algorithm (Seurat RunTSNE function) as described
previously56. The first 15 principal components were used to run the t-SNE
dimensionality reduction. The FindClusters function was run with a resolution
parameter of 0.4, resulting in 14 clusters of cells. These clusters corresponded to
naive CD8+ T cells, B cells, activated CD8+ T cells, macrophages, CD8+ effector
T cells, myeloid cells, dendritic cells (DCs), natural killer cells (NK), CD4+ reg-
ulatory T cells, plasmacytoid dendritic cells (pDCs), and neutrophils. Cluster cell
type identities were determined by examining marker genes specifically expressed
more highly in each cluster (Seurat FindAllMarkers function) and expression of
known immune marker genes (Seurat FeaturePlot function).
5′ mouse TCR a/b cell partitioning, library preparation, sequence, and read
alignment. After sorting for CD45+ or CD8+ T cells from spleens or tumors,
single cells were suspended in PBS with 0.04% BSA (KPL Immunoassays, Cat. # 50-
61-00) were loaded on a Chromium Single Cell Instrument (10X Genomics).
RNAseq and V(D)J libraries were prepared using Chromium Single Cell 5′ Library,
Gel Beads and Multiplex Kit (10X Genomics). After amplification, cDNA was split
into RNAseq and V(D)J library aliquots. To enrich the V(D)J library aliquot for
TCR a/b, the cDNA was split into two 20 ng aliquots and amplified in two rounds
using primers designed in-house. Specifically, for first round amplification the
primers used were MP147 (ACACTCTTTCCCTACACGACGC) for short R1,
MP122 (GGTGCTGTCCTGAGACCGAG) for mouse TRAC, and MP123
(CAATCTCTGCTTTTGATGGCTCAAAC) for mouse TRBC. For second round
amplification, 20 ng aliquots from the first round were amplified using MP147
(ACACTCTTTCCCTACACGACGC) for short R1, MP130 (GTGACTGGAGTT
CAGACGTGTGCTCTTCCGATCTTGGTACACAGCAGGTTCTGG) a nested R2
plus mouse TRAC, and MP131 (GTGACTGGAGTTCAGACGTGTGCTCT
TCCGATCTGACCTTGGGTGGAGTCACATTTCTC) a nested R2 plus mouse
TRABC. V(D)J libraries were prepared from 25 ng each mTRAC and mTRBC
amplified cDNA. Paired-end sequencing was performed on Illumina NextSeq500
for RNAseq libraries (Read 1 26-bp for UMI and cell barcode, 8-bp i7 sample
index, 0-bp i5, and Read 2 55-bp transcript read) and V(D)J libraries (Read 1 150-
bp, 8-bp i7 sample index, 0-bp i5, and Read 2 150-bp read). For RNAseq libraries,
Cell Ranger Single-Cell Software Suite (10X Genomics, v2.2.0) was used to
perform sample demultiplexing, alignment, filtering, and UMI counting. The
mouse mm10 genome assembly and RefSeq gene model for mouse were used for
the alignment. For V(D)J libraries, Cell Ranger Single-Cell Software Suite (10X
Genomics, v2.2.0) was used to perform sample demultiplexing, de novo assembly
of read pairs into contigs, align and annotate contigs against all of the germline
segment V(D)J reference sequences from IMGT, label and locate CDR3 regions,
group clonotypes.
Clonal diversity. The diversity of the TCR repertoire (CDR3 TCR alpha and beta)
was calculated using Shannon diversity index58. The TCR data for each condition
tested are sampled 50 times at each sample size n (ranging across the x axis) giving
the mean and standard deviation of the diversity at each given sample size.
Interpolated means that n is smaller than the actual observed sample size (the
number of CD8+T with full TCR sequences for each group). Extrapolation means
n is larger than the observed sample size with sampling including replacement to
mimic a larger sample size.
Pathway analysis. KEGG pathways enriched in differentially expressed genes were
determined using DAVID59 with an FDR cutoff of 0.05. Heatmaps were generated
for selected enriched pathways using log2 TPM expression values that were scaled
across samples for each gene. A pseudo-count of 1 TPM added to all raw
expression values to avoid infinite values.
Cloning and expression of TCRs. JRT3 cells were generated by transducing with
lentiviruses expressing mouse CD8a, CD8b, and CD28. The cells were also
transduced with a lentivirus expressing AP1.Luc (Qiagen, Cat. # 336851). The
sequences obtained from the TCRseq of intra-tumoral CD8+ T cells were cloned
into lentivirus constructs and stable JRT3 cell lines were generated. To test for their
ability to recognize tumor cells, the stable JRT3 cell lines were incubated with
different amounts of MC38 cells for 6 h. Luciferase activity was measured by
adding luciferase substrate (Promega Cat. E1500) and measuring luminescence on
a luminometer.
LDH assay. Evaluation of CD8+ and cytotoxic functional activity was performed
using the Cytotoxicity Detection Kit LDH (Roche Applied Science, Basel, Swit-
zerland) according to the manufacturer’s protocol. Briefly, CD8+ TILs were iso-
lated from B16F10 tumor using a CD8+ TIL isolation kit (Miltenyi Biotec, Cat. #
130-116-478). Isolation purity was assessed by flow cytometry prior to starting the
LDH assay. Cytotoxicity was calculated according to the following formula: % cell
lysis= (experimental value− effector spontaneous control− targets spontaneous
control) × 100/(target maximum control− target spontaneous control), where
“experimental” corresponds to the experimental signal value, “effector spontaneous
control” to the spontaneous background signal value of the effector cells alone,
“target spontaneous control” to the spontaneous background signal value of target
tumor cells alone, and “target maximum control” to the maximum signal value of
target cells in medium containing 1% Trixton X-100. Cytotoxicity assays were
performed for varying effector cell (E) to target cell (T) ratios, and specific cyto-
toxicity lysis percentages are reported as the mean ± SEM of triplicate samples.
Cytokine analysis. Levels of cytokines in serum or tissue culture supernatant were
measured using the V-PLEX Plus Mouse Cytokine 19-Plex Kit (MSD, Cat. #
K15255G-1) according to the manufacturer’s protocol.
Statistics and reproducibility. Significance values (p values) were calculated with
unpaired two-tailed Student’s t test for two-group comparisons or one-way
ANOVA for multigroup comparisons with Tukey’s comparison test. P values of
<0.05 were considered significant. *P < 0.05; **P < 0.01; ***P < 0.001. Statistical
analyses were performed with Graphpad Prism 8. Each experiment was repeated at
least three times, and sample sizes and numbers are indicated in detail in each
figure legend.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All bulk RNAseq and scRNAseq files have been deposited in the NCBI GEO Database
and can be accessed using GSE151829, GSE151830, and GSE151831. Source data can be
found in Supplementary Data 9.
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